May 10, 2011

FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Delivered by Intradermal Microinjection

Fluzone® Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle

 

FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Delivered by Intradermal Microinjection
Fluzone® Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle

Lyon, France – May 10, 2011 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine). Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.